castletestinfo.com
Open in
urlscan Pro
104.155.149.95
Public Scan
Submitted URL: http://myriadderm.com/
Effective URL: https://castletestinfo.com/mypath-melanoma-diffdx-melanoma/
Submission: On January 06 via manual from US — Scanned from DE
Effective URL: https://castletestinfo.com/mypath-melanoma-diffdx-melanoma/
Submission: On January 06 via manual from US — Scanned from DE
Form analysis 2 forms found in the DOM
GET https://castletestinfo.com/
<form role="search" method="get" class="search-form" action="https://castletestinfo.com/">
<label>
<span class="screen-reader-text">Search for:</span>
<input type="search" class="search-field" placeholder="Search …" value="" name="s" role="search" tabindex="-1">
</label>
<button type="submit" class="search-submit" value="Search" aria-label="search submit"><i class="astra-search-icon"></i></button>
</form>GET https://castletestinfo.com/
<form role="search" method="get" class="search-form" action="https://castletestinfo.com/">
<label>
<span class="screen-reader-text">Search for:</span>
<input type="search" class="search-field" placeholder="Search …" value="" name="s" role="search" tabindex="-1">
</label>
<button type="submit" class="search-submit" value="Search" aria-label="search submit"><i class="astra-search-icon"></i></button>
</form>Text Content
Skip to content
PHYSICIAN LOGIN | RESEARCHER LOGIN
CONTACT A
REPRESENTATIVE
ORDER A
TEST
* DecisionDx®-Melanoma
* Limitations of Traditional Prognostic Approaches
* Staging-Only Method
* Sentinel Lymph Node Biopsy Procedure
* DecisionDx-Melanoma
* Overview
* Understanding DecisionDx-Melanoma Results
* Clinical Validation
* Clinical Utility Studies
* Prospective Studies
* Meta-Analysis/Systematic Reviews and Guidelines
* Analytic Validation
* Test Process
* Ordering and Reporting
* Patient Access
* Resources
* Melanoma Expert Video Series
* On-Demand Educational Programs
* Scientific References
* Additional Cutaneous Melanoma Tests
* DecisionDx®-CMSeq
* myPath® Melanoma | DiffDx™-Melanoma
* Overview of Difficult-to-Diagnose Melanocytic Lesions
* Ambiguity and Discordance
* Why GEP?
* Product Overview
* myPath Melanoma
* DiffDx-Melanoma
* Clinical Evidence
* myPath Melanoma
* DiffDx-Melanoma
* Test Process
* Ordering and Reporting
* Patient Access
* Scientific References
* DecisionDx®-SCC
* SCC Landscape
* High-Risk SCC
* SCC Risk Factors
* Metastasis and Survival
* DecisionDx-SCC
* DecisionDx-SCC Overview
* Clinical Evidence
* Clinical Benefits
* Test Process
* Ordering and Reporting
* Patient Access
* Scientific References
* DecisionDx®-UM
* DecisionDx-UM
* DecisionDx-UM Overview
* Technical Success
* Documented Clinical Use
* Clinical Validation
* Prospective Clinical Validation Studies
* Comparison to Other Prognostic Markers
* Test Process
* Ordering and Reporting
* Patient Access
* Scientific References
* Resources
* Biopsy Resources
* Clinical Sample Repository
* Additional Uveal Melanoma Tests
* DecisionDx®-UMSeq
* DecisionDx®-PRAME
* By Disease
* Cutaneous Melanoma (Prognostic)
* Cutaneous Melanoma (Diagnostic)
* Cutaneous Squamous Cell Carcinoma
* Uveal Melanoma
* Search
Search for:
×
* DecisionDx®-Melanoma
* Limitations of Traditional Prognostic Approaches
* Staging-Only Method
* Sentinel Lymph Node Biopsy Procedure
* DecisionDx-Melanoma
* Overview
* Understanding DecisionDx-Melanoma Results
* Clinical Validation
* Clinical Utility Studies
* Prospective Studies
* Meta-Analysis/Systematic Reviews and Guidelines
* Analytic Validation
* Test Process
* Ordering and Reporting
* Patient Access
* Resources
* Melanoma Expert Video Series
* On-Demand Educational Programs
* Scientific References
* Additional Cutaneous Melanoma Tests
* DecisionDx®-CMSeq
* myPath® Melanoma | DiffDx™-Melanoma
* Overview of Difficult-to-Diagnose Melanocytic Lesions
* Ambiguity and Discordance
* Why GEP?
* Product Overview
* myPath Melanoma
* DiffDx-Melanoma
* Clinical Evidence
* myPath Melanoma
* DiffDx-Melanoma
* Test Process
* Ordering and Reporting
* Patient Access
* Scientific References
* DecisionDx®-SCC
* SCC Landscape
* High-Risk SCC
* SCC Risk Factors
* Metastasis and Survival
* DecisionDx-SCC
* DecisionDx-SCC Overview
* Clinical Evidence
* Clinical Benefits
* Test Process
* Ordering and Reporting
* Patient Access
* Scientific References
* DecisionDx®-UM
* DecisionDx-UM
* DecisionDx-UM Overview
* Technical Success
* Documented Clinical Use
* Clinical Validation
* Prospective Clinical Validation Studies
* Comparison to Other Prognostic Markers
* Test Process
* Ordering and Reporting
* Patient Access
* Scientific References
* Resources
* Biopsy Resources
* Clinical Sample Repository
* Additional Uveal Melanoma Tests
* DecisionDx®-UMSeq
* DecisionDx®-PRAME
* By Disease
* Cutaneous Melanoma (Prognostic)
* Cutaneous Melanoma (Diagnostic)
* Cutaneous Squamous Cell Carcinoma
* Uveal Melanoma
* Search
Search for:
NOW AVAILABLE: A More Objective and Comprehensive Diagnostic Testing Solution
for Difficult-to-Diagnose Melanocytic Lesions. LEARN MORE
Comprehensive Diagnostic Offering
Overview of Difficult-to-Diagnose
Melanocytic Lesions
Up to 300,00 lesions that cannot be confidently diagnosed with H&E alone
Ambiguity and Discordance
Ambiguity and discordance have an impact on clinical decisions
Why GEP?
GEP provides an objective view of cellular biology
Clinical Evidence
myPath® Melanoma | DiffDx™-Melanoma
Test Process
The combined workflow
Scientific References
Over 15 publications including outcomes data
TESTS BY DISEASE
* Cutaneous Melanoma (Prognostic)
* Cutaneous Melanoma (Diagnostic)
* Cutaneous Squamous Cell Carcinoma
* Uveal Melanoma
NEWS & EVENTS
News
CASTLE BIOSCIENCES
* About Us
* History
* Executive Management
* Board of Directors
* Licenses
* Careers
* Contact Us
Customer Service: 866-788-9007
Privacy Policy | Terms of Use
© 2020 Castle Test Info All Rights Reserved.
This site uses cookies to offer you a better browsing experience. Read our
Privacy Policy.
We use cookies and share data with services that improve your experience on this
site. Read our Privacy Policy.
Opt-Out
Accept Decline
Cookie Settings
Do you really wish to opt-out? Close
Cancel Confirm
Scroll to Top